Key result
CRT deactivation in LVAD patients does not reduce arrhythmias but is linked to improved transplant-free survival.
Why the study?
Most LVAD patients with active CRT devices are non-responders, and convincing evidence of clinical benefit from continuing CRT therapy during LVAD support is lacking.
Does deactivating CRT therapy reduce ventricular arrhythmias or improve survival in patients with LVAD support?
Cohort (n=158)
No
Does deactivating CRT therapy reduce ventricular arrhythmias or improve survival in patients with LVAD support?
Deactivating CRT in LVAD patients does not increase ventricular arrhythmias and may be associated with improved transplant-free survival.
Answers are grounded in this paper and cite their sources.
CRT deactivation was associated with better transplant-free survival post-LVAD; observational data leave open need for randomized confirmation.
Background The majority of LVAD patients with an active CRT device are CRT non-responders. Currently, there is no convincing evidence of any clinical benefit from continuing CRT therapy in patients on LVAD support. Objectives This study aimed to evaluate the impact of deactivating CRT therapy in patients with LVAD support on the incidence of ventricular arrhythmias, as well as on transplant-free survival and overall survival. Methods We conducted a retrospective cohort study of 178 patients with active CRT devices who underwent LVAD implantation at our Heart Center between September 2011 and December 2023. Results A total of 158 LVAD patients with an active CRT were included in our study. We excluded patients who received a heart transplant or died during the index hospitalization, in addition to those with CRT duration of less than one month after LVAD implantation. The patients were predominantly male (89%), had NICM (64%), and were on average 63±8 years old. All LVADs were continuous-flow devices (72 HVAD, 8 HeartMate II, and 78 HeartMate 3). In 48 patients (30%) CRT was turned off during the LVAD support for various reasons, most commonly due to LV lead dysfunction. The median time from LVAD implantation to CRT deactivation was 18.5 months. The incidence of ventricular arrhythmias (including both MVT and VF) within the first year after LVAD implantation was comparable between the CRT-on and CRT-off groups (37% vs. 40%, p=0.649). In both univariate (p=0.018) and multivariate analyses, CRT deactivation was associated with improved transplant-free survival (p=0.020, adjusted for sex, age, and underlying cardiomyopathy). The estimated 3-year transplant-free survival was 49% (95% CI: 40–58%) in the CRT-on group and 81% (95% CI: 70–92%) in the CRT-off group. No significant differences in overall survival were observed between the two groups. Conclusions Deactivation of LV lead pacing in LVAD patients with CRT had no impact on the incidence of ventricular tachyarrhythmias and may be associated with improved transplant-free survival.
No takes yet. Share an insight, caveat, or question.
Efimova et al. (2026) conducted a cohort in LVAD patients with an active CRT device (n=158). CRT deactivation vs. CRT continuation (CRT-on) was evaluated on Incidence of ventricular arrhythmias within the first year (p=0.649). CRT deactivation in LVAD patients had no significant impact on 1-year ventricular arrhythmia incidence but was associated with improved 3-year transplant-free survival.
Synapse has enriched 10 related papers. Consider them for comparative context: